The predictive utility of CTCs is currently being investigated: Recent studies such as the STIC-CTC trial or the DETECT-III trial indicate that both their counts and phenotypes such as HER2/neu positivity can be used for drawing decisions to treat breast cancer [4, 5]. This evidence concerns the gene ERBB2 and breast cancer.